Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · November 25, 2015

Prophylactic Minocycline for Erlotinib-Induced Skin Toxicities

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer
J. Clin. Oncol 2015 Nov 16;[EPub Ahead of Print], B Melosky, H Anderson, RL Burkes, Q Chu, D Hao, V Ho, C Ho, W Lam, CW Lee, NB Leighl, N Murray, S Sun, R Winston, JJ Laskin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading